Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 413-415 , April 2004

A study of a genetic association between the PTGS2/PLA2G4A locus and schizophrenia

  • J Wei

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel: +44-1248-354048; fax: +44-1248-353659
    • ,
  • G.P Hemmings

,Accepted 18 December 2003.

References 

  1. Horrobin DF, Glen AI, Hudson CJ. Possible relevance of phospholipid abnormalities, genetic interactions in psychiatric disorder (the relationship between dyslexia and schizophrenia). Med. Hypotheses. 1995;45:605–613
  2. Stevens JD. The distribution of phospholipid fractions in the red cell membrane of schizophrenics. Schizophr. Bull. 1972;6:60–61
  3. Tolbert LC, Monti JA, O’Shields H, Walter-Ryan W, Meadows D, Smythies JR. Defects in transmethylation, membrane lipids in schizophrenia. Psychopharmacol. Bull. 1983;19:594–599
  4. Hitzemann R, Hirschowitz J, Garver D. Membrane abnormalities in the psychosis and affective disorders. J. Psychiatr. Res. 1984;18:319–326
  5. Keshavan MS, Mallinger AG, Pettegrew JW, Dippold C. Erythrocyte membrane phospholipids in psychotic patients. Psychiatr. Res. 1993;49:89–95
  6. Glen AI, Glen EM, Horrobin DF, et al.  A red cell membrane abnormality in a subgroup of schizophrenic patients. Evidence for two diseases. Schizophr. Res. 1994;12:53–61
  7. Pettegrew JW, Keshavan MS, Panchalingam K, et al.  Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1991;48:563–568
  8. Fujimoto T, Nakano T, Takano T, Hokazono Y, Asakura T, Tsuji T. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr. Scand. 1992;86:455–462
  9. Stanley JA, Williamson PC, Drost DJ, et al.  Membrane phospholipid metabolism and schizophrenia (an in vivo 31P-MR spectroscopy study). Schizophr. Res. 1994;13:209–215
  10. Stanley JA, Williamson PC, Drost DJ, et al.  An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch. Gen. Psychiatry. 1995;52:399–406
  11. Potwarka JJ, Drost DJ, Williamson PC, et al.  A1 H-decoupled 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. Biol. Psychiatry. 1999;45:687–693
  12. Klemm S, Rzanny R, Riehemann S, et al.  Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia. Am. J. Psychiatry. 2001;158:958–960
  13. Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia (a replication study). Biol. Psychiatry. 1990;28:495–501
  14. Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK. Increased plasma phospholipase A2 activity in schizophrenic patients (reduction after neuroleptic therapy). Biol. Psychiatry. 1987;22:421–426
  15. Gattaz WF, Schimitt A, Maras A. Increased platelet phospholipase A2 activity in schizophrenia. Schizophr. Res. 1995;16:1–6
  16. Noponen M, Sanfilipo M, Samanich K, et al.  Elevated PLA2 activity in schizophrenics and other psychiatric patients. Biol. Psychiatry. 1993;34:641–649
  17. Ross BM, Hudson C, Erlich J, Warsh JJ, Kish SJ. Increased phospholipid breakdown in schizophrenia (evidence for the involvement of a calcium-independent phospholipase A2). Arch. Gen. Psychiatry. 1997;54:487–494
  18. Ross BM, Turenne S, Moszczynska A, Warsh JJ, Kish SJ. (1999) (differential alteration of phospholipase A2 activities in brain of patients with schizophrenia). Brain Res. 1999;821:407–413
  19. Tavares H, Yacubian J, Talib LL, Barbosa NR, Gattaz WF. Increased phospholipase A2 activity in schizophrenia with absent response to niacin. Schizophr. Res. 2003;61:1–6
  20. Hudson CJ, Kennedy JL, Gotowiec A, et al.  Genetic vairiant near cytosolic phospholipase A2 associated with schizophrenia. Schizophr. Res. 1996;21:111–116
  21. Peet M, Ramchand CN, Lee J, et al.  Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia. Psychiatr. Genet. 1998;8:191–192
  22. Wei J, Lee K-H, Hemmings GP. Is the cPLA2 gene associated with schizophrenia?. Mol. Psychiatry. 1998;3:480–482
  23. Rybakowski JK, Borkowska A, Czerski PM, Dmitrzak-Weglarz M, Hauser J. The study of cytosolic phospholipase A2 gene polymorphism in schizophrenia using eye movement disturbances as an endophenotypic marker. Neuropsychobiology. 2003;47:115–119
  24. Price SA, Fox H, St Clair D, Shaw DJ. Lack of association between schizophrenia and a polymorphism close to the cytosolic phospholipase A2 gene. Psychiatr. Genet. 1997;7:111–114
  25. Chowdari KV, Brandstaetter B, Semwal P, et al.  Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family based samples. Psychiatr. Genet. 2001;11:207–212
  26. Frieboes RM, Moises HW, Gattaz WF, et al.  Lack of association between schizophrenia and the phospholipase-A (2) genes cPLA2 and sPLA2. Am. J. Med. Genet. 2001;105:246–249
  27. Miyashita A, Crystal RG, Hay JG. Human cytosolic phospholipase A2 gene, promoter and exon 1. Nucleic Acids Res. 1995;23:293–301
  28. Heleniak E, O’Desky I. Histamine and prostaglandins in schizophrenia (revisited). Med. Hypotheses. 1999;52:37–42
  29. Ward PE, Sutherland J, Glen EM, Glen AI. Niacin skin flush in schizophrenia (a preliminary report). Schizophr. Res. 1998;29:269–274
  30. Puri BK, Easton T, Das I, Kidanes L, Richardson AJ. The niacin skin flush test in schizophrenia (a replication study). Int. J. Clin. Pract. 2001;55:368–370

PII: S0952-3278(04)00015-8

doi: 10.1016/j.plefa.2003.12.018

Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 70, Issue 4 , Pages 413-415 , April 2004

Article Tools